- Home
- INMB
as 11-20-2024 4:00pm EST
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | BOCA RATON |
| Market Cap: | 109.9M | IPO Year: | 2019 |
| Target Price: | $21.00 | AVG Volume (30 days): | 261.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.47 - $14.74 | Next Earning Date: | 10-31-2024 |
| Revenue: | $42,000 | Revenue Growth: | -81.25% |
| Revenue Growth (this year): | -93.09% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of INmune Bio Inc. Common stock (INMB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Moss David J | INMB | Chief Financial Officer | Sep 30 '24 | Buy | $5.29 | 10,000 | $52,868.00 | 1,285,869 | |
| Tesi Raymond Joseph | INMB | President and CEO | Sep 12 '24 | Buy | $6.38 | 15,380 | $98,047.50 | 1,554,106 | |
| Moss David J | INMB | Chief Financial Officer | Sep 12 '24 | Buy | $6.38 | 7,690 | $49,023.75 | 1,285,869 |
Latest INmune Bio Inc. Common stock News
INMB Breaking Stock News: Dive into INMB Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease
Simply Wall St.
18 days ago
INmune Bio Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.48 loss in 3Q 2023)
GuruFocus.com
20 days ago
INmune Bio Inc (INMB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ...
GlobeNewswire
21 days ago
INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update
GuruFocus.com
22 days ago
INmune Bio Inc (INMB) Q3 2024 Earnings Report Preview: What To Look For
GlobeNewswire
24 days ago
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB
GuruFocus.com
a month ago
Highbridge Capital Management's Strategic Acquisition of INmune Bio Inc Shares
GlobeNewswire
a month ago
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination
Compare INMB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INMB INmune Bio Inc. Common stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.